Business Context and Reporting Period
This Form 8-K Current Report was filed by Nephros, Inc. on June 28, 2007. The filing addresses Item 5.02 regarding the compensatory arrangements of Norman J. Barta, the Company's President and Chief Executive Officer, following the expiration of his prior employment agreement on June 30, 2007.
Key Financial Metrics
The filing does not provide financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on executive compensation terms.
Material Changes
The primary material change is the transition of Mr. Barta's employment status from a fixed-term agreement to an "at-will" basis effective June 28, 2007. Under the new Letter Agreement:
- Base Salary: Set at $285,000 annually.
- Employment Status: Employment is now terminable by either party at any time for any reason.
- Performance Bonuses:
- 10% of salary upon completion of a clinical trial for a second hemodiafiltration device in a significant market region.
- 10% of salary upon the first regulatory approval of that second device in such a region.
- Licensing Bonuses: Eligible for 1% of license fees or technology access fees (not tied to sales) for End Stage Renal Disease therapy machines or dialyzer technology. This is capped at $500,000 per agreement and $2,000,000 in aggregate.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, financial outlook, or discussion of general business risks. The document notes that the Letter Agreement includes standard provisions regarding confidentiality, proprietary information, and non-competition restrictions.
Investor Verification Checklist
- Verify the specific terms of the "at-will" employment arrangement and potential termination implications.
- Confirm the status of the clinical trials and regulatory approvals required to trigger the 10% salary bonuses.
- Review the attached Exhibit 99.1 (Letter Agreement) for the complete legal text of the compensation package.
- Monitor future filings for any licensing agreements that would trigger the 1% fee-based bonus.